Assessment of tumor redox status through (S)-4-(3-[
18 F]fluoropropyl)-L-glutamic acid PET imaging of system x
c activity
- Submitting institution
-
King's College London
- Unit of assessment
- 12 - Engineering
- Output identifier
- 103181719
- Type
- D - Journal article
- DOI
-
10.1158/0008-5472.CAN-18-2634
- Title of journal
- Cancer Research
- Article number
- 79
- First page
- 853
- Volume
- 79
- Issue
- 4
- ISSN
- 0008-5472
- Open access status
- Compliant
- Month of publication
- November
- Year of publication
- 2018
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- Yes
- Number of additional authors
-
16
- Research group(s)
-
-
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- Most cancer patients die from drug-resistant disease. In the clinic there is no accurate way to determine tumour response to treatment at an early stage. Our solution to this problem was to develop a novel PET tracer to assess tumour redox status as a marker of drug efficacy. This tracer detected a positive response to therapy prior to tumour shrinkage (the clinical gold-standard) in animal models of ovarian cancer; subsequently, it was shown to predict response prior to therapy (https://doi.org/10.1158/1078-0432.CCR-18-3423). This tracer has been commercialised (n.koglin@life-mi.com), with eight clinical trials open world-wide (NCT03546868, NCT03103490, NCT03824535, NCT02448225, NCT03144622, NCT02379377, NCT03275974, NCT03263429).
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -